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http://dxBackground: The cardiac support device supports the heart and mechanically reduces left ventricular (LV) di-
astolic wall stress. Although it has been shown to halt LV remodeling in dilated cardiomyopathy, its therapeutic
efficacy is limited by its lack of biological effects. In contrast, the slow-release synthetic prostacyclin agonist
ONO-1301 enhances reversal of LV remodeling through biological mechanisms such as angiogenesis and atten-
uation of fibrosis. We therefore hypothesized that ONO-1301 plus a cardiac support device might be beneficial
for the treatment of ischemic cardiomyopathy.
Methods: Twenty-four dogs with induced anterior wall infarction were assigned randomly to 1 of 4 groups at
1 week postinfarction as follows: cardiac support device alone, cardiac support device plus ONO-1301 (hybrid
therapy), ONO-1301 alone, or sham control.
Results: At 8 weeks post-infarction, LV wall stress was reduced significantly in the hybrid therapy group com-
pared with the other groups. Myocardial blood flow, measured by positron emission tomography, and vascular
density were significantly higher in the hybrid therapy group compared with the cardiac support device alone and
sham groups. The hybrid therapy group also showed the least interstitial fibrosis, the greatest recovery of LV
systolic and diastolic functions, assessed by multidetector computed tomography and cardiac catheterization,
and the lowest plasma N-terminal pro-B-type natriuretic peptide levels (P<.05).
Conclusions: The combination of a cardiac support device and the prostacyclin agonist ONO-1301 elicited
a greater reversal of LV remodeling than either treatment alone, suggesting the potential of this hybrid therapy
for the clinical treatment of ischemia-induced heart failure. (J Thorac Cardiovasc Surg 2014;147:1081-7)Left ventricular (LV) remodeling in ischemic and noni-
schemic dilated cardiomyopathy is characterized by pro-
gressive dilatation and dysfunction of the left ventricle,
leading to severe heart failure.1,2 The cardiac support
device is a mesh net designed to reduce diastolic ventricular
wall stress by mechanical means and thus prevent LV
dilatation. It has been shown to halt LV remodeling in
dilated cardiomyopathy in preclinical studies.3-5 Clinical
trials undertaken on the basis of these favorable results
showed beneficial effects on LV remodeling, including
significantly decreased LV end-systolic (LVESV) and end-
diastolic volumes (LVEDV), and a significant improvement
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SHowever, despite these positive effects, the device has not
been associated with reductions in mortality and has not
been approved for clinical use.9
The synthetic prostacyclin agonist ONO-1301 acts as
amyocardial regenerative biological drug to enhance reversal
of LV remodeling.10-12 The beneficial effects of ONO-1301
on the heart are mediated by up-regulation of angiogenic
and antifibrotic molecules, such as hepatocyte growth factor
(HGF), vascular endothelial growth factor (VEGF), and stro-
mal cell–derived factor-1 (SDF-1).10-12 This mechanism has
been shown to result in the active suppression of ischemic and
fibrotic changes in the myocardium.10-12
We hypothesized that the biological effects of the slow-
release form of the synthetic prostacyclin agonist ONO-
1301might complement themechanical effects of the cardiac
support device, thus enhancing its therapeutic effects in
ischemic cardiomyopathy.
MATERIALS AND METHODS
All animals used in this study received care in compliance with the
Guide for the Care and Use of Laboratory Animals (National Institutes
of Health publication no. 85-23, revised 1996).
Animal Treatment
A total of 28beagles (Oriental Yeast, Co, Ltd, Tokyo, Japan)weighing9 to
11 kg were used. General anesthesia was administered with intramuscular
ketamine (10 mg/kg) and intravenous propofol (5 mg/kg) for induction,diovascular Surgery c Volume 147, Number 3 1081
Abbreviations and Acronyms
ANOVA ¼ analysis of variance
dp/dt ¼ delta pressure/delta time
Ees ¼ end-systolic elastance
HGF ¼ hepatocyte growth factor
LV ¼ left ventricular
LVEDV ¼ left ventricular end-diastolic volume
LVESV ¼ left ventricular end-systolic volume
MDCT ¼ multidetector computed tomography
MI ¼ myocardial infarction
NT-proBNP ¼ amino-terminal pro-brain natriuretic
peptide
SDF-1 ¼ stromal cell–derived factor-1
VEGF ¼ vascular endothelial growth factor




Sand inhaled sevoflurane (1%–2%) for subsequent maintenance, with endo-
tracheal intubation and mechanical ventilator support. After completion
of the experiments, the animals were killed under general anesthesia,
using an overdose of intravenous sodiumpentobarbital (18mg/kg) to achieve
complete sedation, followed by administration of an intravenous potassium-
based solution.
Myocardial Infarction Induction
With the animals under general anesthesia, a minimal left thoracotomy
was performed through the fifth intercostal space, and the heart was
exposed by pericardiotomy. The left descending artery and diagonal vessels
were ligated both proximally and distally using 5-0 polypropylene sutures
to produce an anterior myocardial infarction (MI). Akinesis of the anterior
wall was confirmed by epicardial echocardiography and the chest was
closed in layers. The animals were allowed to recover.
Cardiac Support Device
The cardiac support device (0.9–1.0 g), made from polyglycolic acid
(Nipro Corporation, Osaka, Japan), was designed on the basis of data
obtained from multidetector computed tomography (MDCT) and a heart
excised at 1 week postinfarction.
Treatments
The animals were assigned randomly to 1 of 4 groups at 1 week after
infarct induction as follows: cardiac support device alone, cardiac support
device plus ONO-1301 (hybrid therapy), ONO-1301 alone, or sham control
group. In the cardiac support device alone group, 2 sheets of atelocollagen
(50 3 50 mm) (Integran; Nippon Zoki Pharmaceutical Co, Ltd, Osaka,
Japan) immersed in suspended polylactic and glycolic acid (10 mg/kg)
were fixed on the whole surface of the ventricles and the cardiac support
device was placed as described previously.3-5 The same procedure was
used in the hybrid therapy group, with the addition of ONO-130110-12
(10 mg/kg) (ONO Pharmaceutical Co, Ltd, Osaka, Japan) instead of the
polylactic and glycolic acid. In the ONO-1301 alone group, 2 sheets of ate-
locollagen (50 3 50 mm) immersed in suspended ONO-1301 (10 mg/kg)
were fixed on the whole surface of the ventricles. The sham group was
subjected to the same procedures as the ONO-1301 alone group, except
for the use of polylactic and glycolic acid instead of ONO-1301.
Transthoracic Echocardiography
Transthoracic echocardiography was performed using a 5.0-MHz
transducer (Altida; Toshiba Medical Systems Corporation, Tochigi, Japan)1082 The Journal of Thoracic and Cardiovascular Surfor 2-dimensional speckle-tracking echocardiography under general
anesthesia. The data were analyzed using 2-dimensional Wall Motion
Tracking software (Toshiba Medical Systems Corporation) as previously
described.13
MDCT
Electrocardiography-gated MDCT was performed using a 16-row
MDCT scanner (SOMATOM Emotion 16-Slice Configuration; Siemens,
Munich, Germany) during an end-expiratory breath-hold under general
anesthesia. MDCT was performed after intravenous injection of 30 mL
of nonionic contrast medium (Iomeron; Bracco, Milan, Italy). All images
were analyzed on a workstation (AZE VirtualPlace Lexus64; AZE, Tokyo,
Japan). LVEDV and LVESV, LV ejection fraction, LV end-diastolic and
end-systolic sphericity indices, and LV/right ventricular end-diastolic and
end-systolic diameter values were obtained from the workstation.
Cardiac Catheterization
Under general anesthesia, a 3F micromanometer-tipped catheter
(SPR-249; Millar Instruments, Houston, Tex) was inserted through the
ventricular apex via a left thoracotomy to measure hemodynamic
parameters and cardiac functions, including end-systolic pressure and
end-diastolic pressure, delta pressure/delta time (dp/dt) maximum, dp/dt
minimum, end-systolic elastance (Ees), and the time constant of relaxation
in the left and right ventricles. LV volume was altered by occluding the
inferior vena cava with tape via a left thoracotomy.
Wall Stress Calculation
LV wall stress was evaluated using specifically developed software
(YD, Ltd, Tokyo, Japan) on an off-line personal computer. Global end-
systolic and end-diastolic wall stresses were calculated on the basis of
the data obtained from MDCT and cardiac catheterization.14
Cardiac Positron Emission Tomography
13N-ammonia (200–300 MBq) positron emission tomography (PET) was
performedusing aHeadtomeV/SET2400W (Shimadzu, Co, Kyoto, Japan) un-
der general anesthesia. Myocardial blood flow was quantitated using PMOD
software (version 3.2) (PMOD Technologies, Ltd, Zurich, Switzerland) and
divided into 17 segments as recommendedby theAmericanHeartAssociation.
Histologic Analysis
Paraffin-embedded transverse sections of the excised hearts were stained
with periodic acid-Schiff tomeasure the short-axis diameter of themyocytes,
andwithMasson trichrome to assess the extent of fibrosis. The sectionswere
immunostained with anti-CD31 antibody in LSAB kits (DakoCytomation,
Glostrup, Denmark). Myocyte diameters and vascular density were mea-
sured in 10 different randomly selected fields using a Biorevo BZ-9000 fluo-
rescence microscope (Keyence, Osaka, Japan), and percentage fibrosis was
calculated using MetaMorph software (Molecular Devices, Tokyo, Japan).
Real-Time Polymerase Chain Reaction
Total RNA extracted from cardiac tissue was reverse-transcribed using
TaqMan reverse transcription reagents (Applied Biosystems, Foster City,
Calif), and assayed using the ABI PRISM 7700 (Applied Biosystems).
The average copy number of gene transcripts was normalized to that of
glyceraldehyde 3-phosphate dehydrogenase for each sample.
Statistical Analysis
All statistical analyses were performed using JMP software (JMP9; SAS
institute, Inc, Cary, NC). Results are presented as the mean  standard
deviation. Cardiac catheterization and histologic data were compared by
1-way analysis of variance (ANOVA). MDCT, echocardiography, wall
stress, and amino-terminal pro-brain natriuretic peptide (NT-proBNP)gery c March 2014
FIGURE 1. MDCTanalysis. A, Changes in LVEDV. B, Changes in LVESV. C, Changes in LVejection fraction. D, Changes in left ventricular end-diastolic
and, (E) end-systolic sphericity indices. F, Changes in NT-proBNP. Hybrid therapy is shown by circles with a solid line, a cardiac support device alone is
shown by triangles with a dashed/dotted line, ONO-1301 alone is shown by squares with a dashed line, and sham is shown by crosses with a dotted line.
*P<.05 versus corresponding sham, yP<.05 versus corresponding cardiac support device alone, zP<.05 versus corresponding ONO-1301 alone. LV
sphericity index, LV long-axis diameter/LV short-axis diameter. LVEDV, Left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume;
NT-proBNP, amino-terminal pro-brain natriuretic peptide.
Kubota et al Evolving Technology/Basic Sciencedata were compared by repeated ANOVA, using values obtained by sub-
tracting the values at 1 week postinfarction from the values at each time
point. Significant differences shown by ANOVA were subjected to post
hoc analysis with Bonferroni correction. Sample size justification was
not performed. A P value less than .05 was considered statistically
significant.S
RESULTS
Procedure-Related Morbidity and Mortality
Twenty-four animals completed the study. Three of the
animals that failed to complete the study died within
1 week postinfarction and the remaining animal, which
was a sham control, died at 7 weeks postinfarction. No
dogs developed infections or had insufficient MI.E
T
/BRecovery of Global Cardiac Performance With
Hybrid Therapy
Global cardiac performance after the treatment was as-
sessed serially and comprehensively by MDCT and cardiacThe Journal of Thoracic and Carcatheterization. Both LVEDV and LVESV tended to in-
crease after MI induction in the sham group (Figure 1, A
and B). LVEDVwas significantly smaller in the hybrid ther-
apy group compared with the sham group at 3 and 5 weeks
postinfarction, and significantly smaller than in both the
ONO-1301 alone and sham groups at 8 weeks postinfarc-
tion. LVESV in the hybrid therapy group was significantly
smaller than that in the sham group at 3 and 5 weeks, and
was significantly smaller than that in the other groups at 8
weeks. As a result, LV ejection fraction was significantly
greater in the hybrid therapy group compared with the
sham group at 3 and 5 weeks, and significantly greater
than in the other groups at 8 weeks (Figure 1, C).
The LV end-diastolic sphericity index was significantly
greater in the hybrid therapy group compared with the
ONO-1301 alone and sham groups at 8 weeks postinfarc-
tion (Figure 1, D). The LVend-systolic sphericity index de-
creased in all groups at 1 week postinfarction, whereas at 8
weeks the LV end-systolic sphericity index had decreaseddiovascular Surgery c Volume 147, Number 3 1083
TABLE 1. Cardiac catheterization data
Hybrid therapy Cardiac support device alone ONO-1301 alone Sham
dp/dt maximum (mm Hg/s)
LV 1822  83*,y,z 1584  114 1601  91 1238  127
RV 547  101 450  53 539  79 443  86
Ees (mm Hg/mL)
LV 10  1*,y,z 7  1 8  1 4  1
RV 3  1 3  1 3  1 2  1
dp/dt minimum (mm Hg/s)
LV 1553  61*,y,z 1303  71 1387  64 1061  107
RV 407  59 378  67 412  88 333  78
Time constant of relaxation (s)
LV 33  4*,y 42  3 36  3 47  5
RV 39  6 40  2 38  4 46  6
Data are mean  standard deviation. RV, Right ventricular; LV, left ventricular. *P<.05 versus sham. yP<.05 versus cardiac support device alone. zP<.05 versus ONO-1301
alone.




Sfurther in the sham group, remained the same in the cardiac
support device alone and ONO-1301 alone groups, and
recovered in the hybrid therapy group (Figure 1, E).
In addition, systolic function represented by LV dp/dt
max and Ees at 8 weeks was greater in the cardiac support
device alone and ONO-1301 alone groups compared with
the sham group, whereas the hybrid therapy showed signi-
ficantly greater dp/dt max and Ees than the other groups
(Table 1). LV -dp/dt min, which represents diastolic func-
tion, also was significantly greater in the hybrid therapy
group at 8 weeks than in the other groups. LV time constant
of relaxation, which is also an index of diastolic function,
was significantly smaller in the hybrid therapy group at 8
weeks postinfarction than in the cardiac support device
alone and sham groups. There were no significant
differences in any of these parameters in the right ventricle.
MI induction also resulted in an increase in plasma
NT-proBNP, assessed by an enzyme-linked immunosorbent
assay kit (Cardiopet proBNP; IDEXX Laboratories, Tokyo,
Japan), at 1 week postinfarction (Figure 1, F). NT-proBNP
continued to increase in the sham group, whereas the
increase was suppressed in each of the other groups after
treatment. NT-proBNP decreased gradually in the hybrid
therapy group and was significantly lower than in the
sham group at 5 weeks, and was significantly lower than
in the other 2 groups at 8 weeks.
Functional Recovery of Infarct Border Area With
Hybrid Therapy
Regional LV wall motion was evaluated using speckle-
tracking echocardiography to dissect region-specific func-
tional effects of the treatment. The infarct area showed
a significant and marked reduction in the radial strain after
induction of MI, with no significant differences among the
4 groups (Table 2). Radial strain levels in the border area
decreased similarly in all groups at 1 week postinfarction,
although at 8 weeks the hybrid therapy group showed the
greatest recovery in this area. There was a marked decrease1084 The Journal of Thoracic and Cardiovascular Surin radial strain in the remote area in the sham group at 8
weeks, but there was little change throughout the study in
the other groups.Reduction in Global End-Systolic/Diastolic Wall
Stress With Hybrid Therapy
Changes in global end-systolic/end-diastolic wall
stresses after treatment were assessed from MDCT and
catheterization data (Table 2). Similar increases in global
end-systolic wall stress were observed in all groups at 1
week postinfarction. At 8 weeks postinfarction, however,
there was a further increase in the sham group, a slight re-
duction in the cardiac support device alone group, and
almost no change in the ONO-1301 alone group, whereas
global end-systolic wall stress was lowest in the hybrid ther-
apy group. Similar increases in global end-diastolic wall
stress were observed in all groups at 1 week postinfarction.
The sham group showed a marked increase at 8 weeks post-
infarction, whereas the hybrid therapy and cardiac support
device alone groups showed notable reductions. Global
end-diastolic wall stress was significantly lower in the hy-
brid therapy group compared with the ONO-1301 alone
and sham groups at 8 weeks.ONO-1301 Induced Angiogenic Myocardial Effects
in Chronic MI
The angiogenic effects of the treatment were evaluated
by assessing global myocardial blood flow at rest by
13N-ammonia PET at 8 weeks postinfarction. Myocardial
blood flow in the hybrid therapy group was similar to that
in the ONO-1301 group, and both were significantly higher
than in the cardiac support device alone and sham groups
(Figure 2). Capillary densities in the border and remote
areas at 8 weeks postinfarction, which was measured by
immunostaining for CD31, was significantly greater in the
hybrid therapy group than in the cardiac support device
alone and sham groups (Figure 3, A).gery c March 2014
TABLE 2. Regional left ventricular wall motion and global left ventricular wall stress
Hybrid therapy Cardiac support device alone ONO-1301 alone Sham
Radial strain in the MI area (%)
Pre-infarction 21.4  2.3 20.9  1.0 21.7  2.4 22.4  2.3
1 week post-infarction 7.1  1.0 6.7  0.7 7.5  0.9 7.0  1.0
8 weeks postinfarction 8.7  1.2 7.3  0.4 7.5  1.3 6.7  1.0
Radial strain in the border area (%)
Pre-infarction 22.2  2.6 21.8  2.5 22.0  1.6 21.3  1.8
1 week postinfarction 10.4  1.9 10.3  1.9 11.2  1.5 11.5  1.9
8 weeks postinfarction 14.7  1.1*,y,z 10.8  0.2 13.1  1.7 8.1  1.1
Radial strain in the remote area (%)
Pre-infarction 20.7  2.3 21.6  2.0 21.0  2.8 21.2  2.7
1 week postinfarction 19.2  2.1 20.5  1.2 20.9  2.2 19.6  2.0
8 weeks postinfarction 20.2  1.8* 19.7  1.1 20.1  1.5 14.8  1.4
Global end-systolic wall stress (kdyne/cm2)
Pre-infarction 79.9  6.8 84  12.0 80.5  8.1 87.6  9.5
1 week postinfarction 108.1  9.1 104.8  11.9 102.7  11.4 107.5  9.6
8 weeks postinfarction 84  5.7*,y,z 97.7  11.4 104.6  10.0 161.9  9.3
Global end-systolic wall stress (kdyne/cm2)
Pre-infarction 13.0  1.5 11.5  1.1 12.0  1.3 12.0  1.6
1 week postinfarction 17.9  1.5 17.1  1.0 17.0  1.4 16.4  2.5
8 weeks postinfarction 14.0  2.5*,z 14.0  1.8 18.0  1.5 24.4  3.6
Data are mean  standard deviation. MI, Myocardial infarction. *P<.05 versus sham. yP<.05 versus cardiac support device alone. zP<.05 versus ONO-1301 alone.
Kubota et al Evolving Technology/Basic ScienceHistologic Evidence of Reversal of LV Remodeling
With Hybrid Therapy
Pathologic cardiomyocyte hypertrophy and interstitial
fibrosis in the border and remote areas at 8 weeks postin-
farction were assessed by periodic acid-Schiff and Masson
trichrome staining, respectively, to evaluate the degree of
reversal of LV remodeling induced by each treatment
(Figure 3, B and C). Cardiomyocyte diameters wereFIGURE 2. A, Global myocardial blood flow assessed by PETat 8 weeks postin
by the American Heart Association. *P<.05 versus sham, yP<.05 versus car
The Journal of Thoracic and Carsignificantly smaller in the border area in the hybrid therapy
group compared with the ONO-1301 alone and sham
groups, and were significantly smaller in the remote area
compared with the sham group. In addition, there was sig-
nificantly less interstitial fibrosis in the hybrid therapy
group compared with the cardiac support device alone,
ONO-1301 alone, and sham groups in the border area,
and less than in the sham group in the remote area.farction. B, Myocardial blood flow divided into 17 segments recommended
diac support device alone.





FIGURE 3. Histologic evaluation at 8 weeks postinfarction. A, Capillary density, (B) myocyte short-axis diameter, and (C) interstitial fibrosis in the border
and remote areas. Expression levels of (D) HGF, (E) VEGF, and (F) SDF-1 in the border and remote areas quantified by real-time polymerase chain reaction
at 8 weeks postinfarction. *P<.05 versus sham, yP<.05 versus cardiac support device alone.GAPDH, Glyceraldehyde 3-phosphate dehydrogenase;HGF,
hepatocyte growth factor; VEGF, vascular endothelial growth factor; SDF-1; stromal cell–derived factor-1.




SUp-Regulation of Cardiac Protective Factors
Real-time polymerase chain reaction was performed at
8 weeks postinfarction to determine the effects of the
treatment on gene expression of major cardiac protective
factors, such as HGF, VEGF and SDF-1 (Figure 3, D-F).
Expression of HGF, VEGF, and SDF-1 in both the border
and remote areas were similar in the hybrid therapy and
ONO-1301 groups, and significantly higher in these 2
groups than in the cardiac support device alone and sham
groups (P<.05).DISCUSSION
This study examined the therapeutic efficacy of hybrid
therapy, comprising a cardiac support device and a synthetic
prostacyclin agonist (ONO-1301), in a canine model of
ischemic cardiomyopathy, compared with the efficacy of
either treatment alone. Hybrid therapy significantly im-
proved both systolic and diastolic functions and reduced
LV wall stress compared with the other treatments, and his-
tologic examination indicated significantly greater reversal
of LV remodeling in the hybrid therapy group. These results
were reflected by a significantly greater reduction of NT-
proBNP by hybrid therapy.
The cardiac support device used in this study comprised
a net made of polyglycolic acid, which is a hydrolytically
bioabsorbable polymer. This represents a major difference1086 The Journal of Thoracic and Cardiovascular Surfrom the net used in previous studies,3-5 and was designed
to remain around the heart for approximately 10 weeks by
adjusting the diameter of the thread. The cardiac support
device remained in place at 8 weeks postinfarction, although
it had become hydrolyzed to some extent. Our net was
functionally equivalent to the nets used in previous studies;
it prevented dilatation of the left ventricle, improved the LV
sphericity index, and reduced diastolic LV wall stress, thus
avoiding the positive feedback loop of cardiac dilatation,
the change from an efficient ellipsoidal to a spherical LV
chamber, interstitial fibrosis, and, ultimately, heart failure
that occurs in ischemic dilated cardiomyopathy.9 However,
one disadvantage of this bioabsorbable net is that it could al-
low LV remodeling to progress after absorption. The present
study did not investigate this aspect and further studies are
needed to assess the relative advantages and disadvantages
of bioabsorbable and nonabsorbable cardiac support devices.
ONO-1301 is a synthetic prostacyclin agonist that is not
yet used in clinical practice. However, several experimental
studies have shown its therapeutic efficacy in ischemic and
nonischemic cardiomyopathy.10-12 ONO-1301was adminis-
tered to the heart differently in the current study compared
with previous studies,10-12 but its plasma concentrations and
reversal of LV remodeling were similar to those seen in
previous studies, suggesting that this mode of administration
was appropriate. In addition, ONO-1301 administration by
incorporation in the cardiac support device could decreasegery c March 2014
Kubota et al Evolving Technology/Basic Scienceadverse effects such as hypotension, which may occur with
systemic administration. Finally, LV remodeling generally
progresses slowly, and long-term drug efficacy therefore is
necessary. ONO-1301 has a slow-release time of approxi-
mately 4 weeks, and thusmay be a suitable agent for the pre-
vention of remodeling.
The favorable results of the current study regarding use of
hybrid therapy may be attributed to the angiogenic and ac-
tive antifibrotic effects of ONO-1301, acting via HGF,
VEGF, and SDF-1, which complemented the mechanical
effects of the cardiac support device with a consequent en-
hancement of therapeutic efficacy. Up-regulation of these
cytokines and increased capillary density were observed
in the hybrid therapy group, whereas PET examination
showed significantly greater myocardial blood flow in the
hybrid therapy group compared with the cardiac support de-
vice alone and sham groups. The additional benefits of
ONO-1301 resulted in enhanced recovery of radial wall
strain and the suppression of interstitial fibrosis in the bor-
der area in the hybrid therapy group, with consequent recov-
ery of cardiac function.
This study was limited by the use of a canine model,
which may not completely reflect clinical ischemic cardio-
myopathy pathologies. In this experiment, there was no
atherosclerosis, and no use of drugs such as b-blockers
and angiotensin-converting enzyme inhibitors, which
might be used in the clinical arena. However, a similar ca-
nine ischemic cardiomyopathy model has been established
previously,2,12 and it is possible to use this model to assess
cardiac function and evaluate the therapeutic effects of
interventions. Our model therefore was deemed adequate
to show the therapeutic effects of the hybrid therapy with
various modalities used in the clinical arena. However,
this model may not be suitable for further studies of the
mechanisms of hybrid therapy, and rodent models may
be better suited for such investigations. This study also
was limited in that it was not clear whether remodeling
would remain suppressed even after complete absorption
of the cardiac support net because the net remained at
the end of this study. Therefore, longer-term studies last-
ing after absorption of the biodegradable net will be
necessary.The Journal of Thoracic and CarThe authors thank Shigeru Matsumi, Toshika Senba, Masako
Yokoyama, and Akima Harada for excellent technical assistance.References
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